[ad_1] Pleased to co-edit the 2nd of 2 #genetherapy issues of International Ophthalmology Clinics: https://t.co/a8F5iOhnzM “DNA- and RNA-based Gene Therapies in Ophthalmology: Inherited and Noninherited Retinal Disorders”. #eye #ophthalmology #retina #gene #IRD #clinicalresearch https://t.co/9OOouvupAR [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @eyewireplus: .@BauschLomb and @clearsidebio announced that the FDA has approved Xipere (triamcinolone acetonide injectable suspension)… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @OTEurope: Triamcinolone acetonide for suprachoroidal injection for treatment of uveitic macular oedema approved by US FDA #Ophthalmolog…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @Genes_MDPI: Genes EBM @ThomasCiullaMD has been interviewed by @retinapodcast on career development and advances in retina therapeutics.… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ThomasCiullaMD: FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for #Suprachoroidal Use for the Treatment of Ma… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for #Suprachoroidal Use for the Treatment of Macular Edema Associated with #Uveitis, the first product approved for injection into the suprachoroidal space. #eye #retina
https://t.co/R2wcsmOZP4
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] @drmarirodriguez @RetinaPodcast Thanks so much for your kind comments! [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Honored to have been interviewed by @retinapodcast on research, roles in industry, and innovations in retinal therapeutics and delivery… #eye #retina #clinicalresearch #genetherapy #suprachoroidal https://t.co/H4aPQAbPPH [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Just published: Retinal Physician-Current Clinical Trials in Diabetic Macular Edema
Innovative therapies with durability & novel mechanisms include pan-VEGF Inhibitors, Ang2 inhibitors, plasma kallikrein inhibitors & anti-integrin therapies.
#eye #retina
https://t.co/lAvvtLQKfS
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Congrats to colleagues with OIS & #ASRS presentations on #suprachoroidal delivery via the SCS Microinjector: clinically studied therapies – a corticosteroid, CLS-AX TKI, #genetherapy, & virus-like drug conjugate for macular edema, #AMD, #diabeticretinopathy, & choroidal melanoma https://t.co/iRHVakqmeO [ad_2] Source by Thomas Ciulla, MD, MBA …